// Shaohua Xu 1,* , Guang-Bo Fu 2,* , Zhen Tao 4 , Jun OuYang 5 , Fanfei Kong 1 , Bing-Hua Jiang 6,7 , Xiaoping Wan 1 and Ke Chen 3 1 Department of Obstetrics and Gynecology, Shanghai First Matenity and Infant Hospital, Tongji University School of Medicine, Shanghai, China 2 Department of Urology and Pathology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China 3 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 4 Department of Science and Technology, Radiation Oncology Department, Tianjin Medical University Cancer Hospital and Institute, Tianjin, China 5 Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Changzhou, China 6 State Key lab of Reproductive Medicine, Cancer Center, Nanjing Medical University, China 7 Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA * These authors have contributed equally to this work Correspondence to: Xiaoping Wan, email: // Ke Chen, email: // Keywords : miR-497, mTOR, p70S6K1, cisplatin resistance, ovarian cancer Received : January 13, 2015 Accepted : June 25, 2015 Published : July 03, 2015 Abstract The mechanism of cisplatin resistance in ovarian cancer is not clearly understood. In the present investigation, we found that the expression levels of miR-497 were reduced in chemotherapy-resistant ovarian cancer cells and tumor tissues due to hypermethylation of miR-497 promoter. Low miR-497 expression levels were associated with chemo-resistant phonotype of ovarian cancer. By analyzing the expression levels of miR-497, mTOR and p70S6K1 in a clinical gene-expression array dataset, we found that mTOR and p70S6K1, two proteins correlated to chemotherapy-resistance in multiple types of human cancers, were inversely correlated with miR-497 levels in ovarian cancer tissues. By using an orthotopic ovarian tumor model and a Tet-On inducible miR-497 expression system, our results demonstrated that overexpression of miR-497 sensitizes the resistant ovarian tumor to cisplatin treatment. Therefore, we suggest that miR-497 might be used as a therapeutic supplement to increase ovarian cancer treatment response to cisplatin.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2015) studied this question.